
WHAT IS CLAIMED IS:

1. Use of ~~A method of treating a hematological malignancy in a subject in need thereof, the method comprising administering to the subject:~~


a compound of formula (I):



(I),

or a pharmaceutically acceptable salt thereof,~~;~~ and

a compound of formula (II):



(II),

or a pharmaceutically acceptable salt and/or solvate thereof, in the manufacture of a medicament for treating a hematological malignancy in a subject in need thereof, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, are to be administered to the subject.

2. The ~~method~~ use of claim 1, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, are to be administered concurrently.

3. The ~~method~~ use of claim 1, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, are to be administered sequentially.

4. The ~~method~~ use of any one of claims 1 to 3, wherein the administration of the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, provides a synergistic effect.

5. The ~~method~~ use of any of claims 1 to 4, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, are to be each administered orally.

6. The ~~method~~ use of any one of claims 1 to 5, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is to be administered at a dose of from about 0.1 mg to about 10 mg.

7. The use~~method~~ of any one of claims 1 to 6, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is to be administered at a dose of from about 0.25 mg to about 4.5 mg.

8. The ~~method~~ use of any one of claims 1 to 7, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is to be administered at a dose of 0.25 mg, 0.5 mg, 0.75 mg, 1.0 mg, 1.25 mg, 1.5 mg, or 2.0 mg.

9. The ~~method~~ use of any one of claims 1 to 8, wherein the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, is to be administered in an amount of from about 50 mg to about 500 mg.

10. The ~~method~~ use of any one of claims 1 to 9, wherein the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, is to be administered in an amount of about 400 mg.

11. The ~~method~~ use of any one of claims 1 to 10, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is to be administered once daily.


12. The ~~method~~ use of any one of claims 1 to 11, wherein the compound of formula (II), or the pharmaceutically acceptable salt thereof, is to be administered once daily.

13. The ~~method~~ use of any one of claims 1 to 12, wherein the compound of formula (II) or a pharmaceutically acceptable salt and/or hydrate thereof is to be administered.

14. The ~~method~~ use of any of claims 1 to 13, wherein the dihydrochloride monohydrate of the compound of formula (II) is to be administered.

15. Use of ~~A method of treating a hematological malignancy in a subject in need thereof, the method comprising administering to the subject:~~


a compound of formula (I):



(I),

or a pharmaceutically acceptable salt thereof~~,~~; and

a compound of formula (III):



(III),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a hematological malignancy in a subject in need thereof, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (III), or the pharmaceutically acceptable salt thereof, are to be administered to the subject.

16. The ~~method~~ use of claim 15, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (III), or the pharmaceutically acceptable salt ~~and/~~ thereof, are to be administered concurrently.

17. The ~~method~~ use of claim 15, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (III), or the pharmaceutically acceptable salt thereof, are to be administered sequentially.

18. The ~~method~~ use of any one of claims 15 to 17, wherein the administration of the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (III), or the pharmaceutically acceptable salt thereof, provides a synergistic effect.

19. The ~~method~~ use of any of claims 15 to 18, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, and the compound of formula (III), or the pharmaceutically acceptable salt thereof, are to be each administered orally.

20. The ~~method~~ use of any one of claims 15 to 19, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is to be administered at a dose of from about 0.1 mg to about 10 mg.

21. The ~~method~~ use of any one of claims 15 to 20, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is to be administered at a dose of from about 0.25 mg to about 4.5 mg.

22. The ~~method~~ use of any one of claims 15 to 21, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is to be administered at a dose of 1.25 mg, 2.0 mg, 3.0 mg, 4.0 mg, or 4.5 mg.

23. The ~~method~~ use of any one of claims 15 to 22, wherein the compound of formula (III), or the pharmaceutically acceptable salt thereof, is to be administered in an amount of from about 5 mg to about 50 mg.

24. The ~~method~~ use of any one of claims 15 to 23, wherein the compound of formula (III), or the pharmaceutically acceptable salt thereof, is to be administered in an amount of about 15 mg.


25. The ~~method~~ use of any one of claims 15 to 24, wherein the dose of the compound of formula (III), or the pharmaceutically acceptable salt thereof, is to be administered twice a day.

26. The ~~method~~ use of any one of claims 15 to 25, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is to be administered once daily.

27. The ~~method~~ use of any one of claims 15 to 25, wherein the dose of the compound of formula (I), or the pharmaceutically acceptable salt thereof, is to be administered twice a day.

28. The ~~method~~ use of any one of claims 15 to 27, wherein the phosphoric acid salt of the compound of formula (III) is to be administered.

29. Use of ~~A method of treating a hematological malignancy in a subject in need thereof, the method comprising administering to the subject~~ a compound of formula (I):



(I),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a hematological malignancy in a subject in need thereof, wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof is to be administered to the subject.

30. The ~~method~~ use of claim 29, wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is to be administered at a dose of from about 0.1 mg to about 10 mg; preferably at a dose of from about 0.25 mg to about 4.5 mg; more preferably at a dose of 0.25 mg, 0.5 mg, 0.75 mg, 1.25 mg, or 2.0 mg.

31. The ~~method~~ use of any one of claims 1 to 30, wherein the hematological malignancy is a myeloproliferative neoplasm.

32. The ~~method~~ use of claim 31, wherein the myeloproliferative neoplasm is myelofibrosis.

33. The ~~method~~ use of claim 32, wherein the myelofibrosis is relapsed/refractory myelofibrosis.

34. The ~~method~~ use of any one of claims 1 to 33, wherein the subject is treatment naïve.

35. The ~~method~~ use of any one of claims 1 to 33, wherein the subject has previously been treated with ruxolitinib.

36. The ~~method~~ use of claim 32, wherein the myelofibrosis is primary myelofibrosis.

37. The ~~method~~ use of claim 36, wherein the primary myelofibrosis is selected from intermediate risk primary myelofibrosis and high risk primary myelofibrosis.

38. The ~~method~~ use of claim 32, wherein the myelofibrosis is secondary myelofibrosis.

39. The use~~method~~ of claim 32, wherein the myelofibrosis is post-essential thrombocythemia myelofibrosis.


40. The use~~method~~ of claim 32, wherein the myelofibrosis is post-polycythemia vera myelofibrosis.

41. The use~~method~~ of claim 31, wherein the myeloproliferative neoplasm is polycythemia vera.

42. The use~~method~~ of claim 31, wherein the myeloproliferative neoplasm is essential thrombocythemia.

43. The use~~method~~ of any one of claims 1 to 30, wherein the hematological malignancy is acute myeloid leukemia (AML).


44. A composition comprising a compound of formula (I):



(I),

or a pharmaceutically acceptable salt thereof; and


a compound of formula (II):



(II),

or a pharmaceutically acceptable salt and/or solvate thereof.


45. A composition comprising a compound of formula (I):



(I);

or a pharmaceutically acceptable salt thereof; and

a compound of formula (III):



(III);

or a pharmaceutically acceptable salt thereof.

46. Use of the composition of claim ~~40~~ 44 or ~~41~~ 45 for the manufacture of a medicament for treatment of a hematological malignancy.

47. A pharmaceutical composition comprising the composition of claim 44 or 45, and a pharmaceutically acceptable carrier.

48. The pharmaceutical composition of claim 44 or 45 for use in the treatment of a hematological malignancy.

49. The composition of claim 44 for use in therapy.

50. The composition of claim 45 for use in therapy.

~~48.~~